CalciMedica, Inc.
General ticker "CALC" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $33.5M (TTM average)
CalciMedica, Inc. does not follow the US Stock Market performance with the rate: -23.3%.
Estimated limits based on current volatility of 3.5%: low 1.56$, high 1.68$
Factors to consider:
- Total employees count: 16 (+14.3%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Limited operating history, Need additional capital, Clinical trial failure, Regulatory and compliance, Labor/talent shortage/retention
- Current price 86.5% below estimated low
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [11.81$, 36.15$]
- 2026-12-31 to 2027-12-31 estimated range: [6.80$, 22.56$]
Financial Metrics affecting the CALC estimates:
- Negative: with PPE of -3.1 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -0.02 <= 2.37
- Negative: negative Net income
- Negative: Shareholder equity ratio, % of -48.86 <= 7.04
- Negative: negative Industry operating cash flow (median)
- Negative: 0 < Interest expense per share per price, % of 0
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: -0.37 < Inventory ratio change, % of 0
Short-term CALC quotes
Long-term CALC plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $38.08MM | $24.20MM | $23.12MM |
| Operating Income | $-38.08MM | $-24.20MM | $-23.12MM |
| Non-Operating Income | $3.72MM | $10.50MM | $-6.44MM |
| Interest Expense | $0.00MM | $0.00MM | $1.42MM |
| R&D Expense | $15.86MM | $14.48MM | $15.23MM |
| Income(Loss) | $-34.36MM | $-13.70MM | $-29.56MM |
| Net Income(Loss)* | $-34.36MM | $-13.70MM | $-29.56MM |
| Stockholders Equity | $8.16MM | $14.41MM | $-6.64MM |
| Assets | $12.19MM | $19.79MM | $13.59MM |
| Operating Cash Flow | $-25.73MM | $-21.15MM | $-21.18MM |
| Capital expenditure | $0.08MM | $0.01MM | $0.03MM |
| Investing Cash Flow | $8.88MM | $-4.42MM | $9.55MM |
| Financing Cash Flow | $20.90MM | $27.97MM | $15.21MM |
| Earnings Per Share** | $-38.26 | $-6.09 | $-0.01 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.